



April 3rd, 2024

<Press Release>

LiberoThera Co., Ltd.

Presentation of anti-CCR8 antibody data at the American Association for Cancer Research Annual Meeting 2024

LiberoThera Co., Ltd. ("LiberoThera") and Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") will present new data for development and characterization of fully human monoclonal antibodies targeting CCR8 at the American Association for Cancer Research (AACR) Annual Meeting, April 5-10, 2024, in San Diego, California.

Title: Identification of fully human CCR8 antibodies that demonstrate excellent ADCC function, potent blocking activity, and robust anti-tumor immune responses

Section 52, Poster board 18

Monday Apr 8, 9:00 AM - 12:30 PM

About CCR8 antibodies

CCR8 is a G-protein-coupled receptor (GPCR), which is predominantly expressed on tumor Tregs. The development of CCR8-specific human antibodies to target tumor Tregs is a promising therapeutic strategy for future cancer treatment.

Under the strategic collaboration of LiberoThera and Biocytogen, fully human antibodies specific bind to human CCR8 were generated using LiberoThera's outstanding membrane antigen preparation technology combined with Biocytogen's advanced antibody discovery platform based on fully human antibody RenMab™ mice. These antibodies bind to both human and mouse CCR8 expressing cell with similar EC₅₀, efficiently inhibit CCL1 induced calcium flux in human CCR8 overexpressed 293T cells and demonstrate potent in vivo anti-tumor effect in CCR8 humanized mouse models.

About Biocytogen

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative

technologies. Using its proprietary RenMab™ /RenLite™ mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. For more information, visit <http://en.biocytogen.com.cn/>.

About LiberoThera

LiberoThera is a drug discovery company targeting membrane proteins including GPCRs. The company was established in 2018 based on the novel membrane protein synthesis technologies invented at RIKEN. LiberoThera is developing novel therapeutic candidates targeting physiologically important membrane proteins. For more information, visit <https://www.liberothera.com/>

LiberoThera's Contact

info@liberothera.com